Business
Total Voting Rights
Futura Medical plc has announced its total issued share capital as of December 31, 2025, stands at 581,327,755 Ordinary Shares, with no shares currently held in treasury, meaning the total number of voting rights is also 581,327,755. This figure will serve as the denominator for shareholders calculating their notification requirements under the FCA's Disclosure and Transparency Rules. Disclaimer*
About this update from Futura Medical Plc
[{"type":"text","content":"\n\n31 December 2025\nFutura Medical plc\n(\"Futura\", \"the Group\" or the \"Company\")\nTotal Voting Rights\n \nFutura Medical plc (AIM: FUM), the pharmaceutical company developing innovative sexual health products, announces that for the purposes of the FCA's Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 581,327,755 Ordinary Shares.\n \nSince the Company currently holds no shares in treasury, the total number of voting rights in the Company is 581,327,755 and this figure may therefore be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.\n \nContacts:\n\n\n\n\nFutura Medical plc\n \n \n\n\nAlex Duggan\nChief Executive Officer\nAngela Hildreth\nFinance Director and COO\n \n\n\[email protected]\n+44 (0)1483 685 670\nwww.futuramedical.com\n \n\n\n\n\nPanmure Liberum\nNominated Adviser\nand Broker\n\n\nEmma Earl, Will Goode, Mark Rogers (Corporate Finance)\n \n\n\n+44 (0)20 3100 2000\n \n \n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nTurner Pope Investments (TPI) Ltd - Broker\n\n\nGuy McDougall, Andrew Thacker\n\n\n+44 (0) 20 3657 0050\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nAlma Strategic Communications\n\n\nRebecca Sanders-Hewett, Sam Modlin, Emma Thompson\n\n\n+44 (0)20 3405 0205\[email protected]\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nNotes to Editors:\n \nFutura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon® and development products WSD4000 and Eroxon® Intense. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.\n \nSexual health issues are prevalent in both men and women. Erectile Dysfunction (\"ED\") impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. Around 60% of women experience at least one symptom of sexual dysfunction, and only one in four women seek professional help, and remain chronically und...